medigraphic.com
ISSN 1561-2929 (Print)

2014, Number 1

<< Back Next >>

RCAN 2014; 24 (1)

On the association between blood lipids and the presence of regional atherosclerosis

Hernández CJL

Language: Spanish
References: 80
Page: 17-34
PDF size: 365.71 Kb.


ABSTRACT

Rationale: Manifestations of atherosclerosis could be dependent upon the state of blood lipids. Study design: Analytical, retrospective. Study serie: 202 patients (Males: 70.8%; Age: 49.5 ± 11.6 years) in whom a Digital Subtraction Angiography (DSA) due to clinical manifestations of regional atherosclerosis. Patients were distributed according with observed lesion of arterial tree: Lesion absent: 11.4%; Coronary lesion: 11.9%; Vascular brain lesion: 18.8%; and Peripheral arterial lesion: 57.9%; respectively. Materials and methods: Completed blood lipid profiles were recovered for studied patients. Association between observed values of blood lipids and the presence of regional atherosclerotic lesion was assessed. Results: Patients with lesion of the coronary tree showed raised values of serum triglycerides. Patients with vascular brain atherosclerosis exhibited diminished HDL figures. Conclusions: Association between blood lipids and regional atherosclerosis was not as strong as anticipated. Patients with damage of several arterial vessels within a specified region showed normal (or moderately increased) values of blood lipids. Studied association might have been modified by patient´s sex. Conduction of prospective studies with non-invasive techniques are recommended in order to further dwell upon the link between dyslipidemia and regional atherosclerosis.


REFERENCES

  1. Negi S, Anand A. Atherosclerotic coronary heart disease- Epidemiology, classification and management. Cardiovasc Hematol Disord Drug Targets 2010;10:257-61.

  2. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: The pathologists' view. Eur Heart J 2013;34:719-28.

  3. Arenillas JF. Intracranial atherosclerosis: Current concepts. Stroke 2011;42(1 Suppl):S20-S29.

  4. Jeng JS, Tang SC, Liu HM. Epidemiology, diagnosis and management of intracranial atherosclerotic disease. Expert Rev Cardiovasc Ther 2010;8:1423-32.

  5. Abdulhannan P, Russell DA, Homer- Vanniasinkam S. Peripheral arterial disease: A literature review. Br Med Bull 2012;104:21-39.

  6. Wennberg PW. Approach to the patient with peripheral arterial disease. Circulation 2013; 128:2241-50.

  7. Meier P, Lansky AJ, Baumbach A. Almanac 2013: Acute coronary syndromes. Heart 2013; 99:1488-93.

  8. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010.The Lancet 2013;380:2095-2128.

  9. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Bruce Ferguson T, et al., on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics- 2010 Update. A report from the American Heart Association. Circulation 2010;121:948-54.

  10. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013;382:1329-40.

  11. Porrata C, Rodríguez-Ojea A, Jiménez S, Peña, M, Bacallao J. The epidemiologic transition in Cuba. En: Obesity and poverty: A new public health challenge (Editores: Peña M, Bacallao J). Pan American Health Organization. Washington, DC: 2000. pp. 51-65.

  12. Ordúñez P, Cooper RS, Espinosa Brito AD, Iraola Ferrer MD, Bernal Muñoz JL, La Rosa Linares Y. Enfermedades cardiovasculares en Cuba: Determinantes para una epidemia y desafíos para la prevención y control. Rev Cubana Salud Pública 2005;31(4): 0-0. Disponible en: http://scielo.sld.cu/scielo.php?script=sci _arttext&pid=S0864- 34662005000400002&lng=es. Fecha de última visita: 11 de Enero del 2014.

  13. Seuc AH, Domínguez Alonso E, Torres Vidal RM, Varona Pérez P. Algunas precisiones acerca de la mortalidad por enfermedades cardiovasculares en Cuba. Rev Cubana Salud Pública 2011;37(1):0- 0. Disponible en: http://scielo.sld.cu/scielo.php?script=sci _arttext&pid=S0864- 34662011000100004&lng=es. Fecha de última visita: 11 de Enero del 2014.

  14. Anónimo. Anuario Estadístico de la Salud. 2013. MINSAP Ministerio de Salud Pública. La Habana: 2013. Disponible en: http://bvscuba.sld.cu/anuario-estadisticode- cuba/. Fecha de última visita: 10 de Enero del 2014.

  15. Tomey MI, Narula J, Kovacic JC. Year in Review: Advances in understanding of plaque composition and treatment options. J Am Coll Cardiol 2014. Epub ahead of print: S0735-1097(14)01088-2.

  16. Niccoli G, Liuzzo G, Montone RA, Crea F. Advances in mechanisms, imaging and management of the unstable plaque. Atherosclerosis 2014;233:467-77.

  17. Kihara S. Dyslipidemia. Nihon Rinsho 2013;71:275-9.

  18. Srikanth S, Deedwania P. Hypertension as a cardiometabolic risk. Indian Heart J 2010;62:394-401.

  19. Raghavan VA. Insulin resistance and atherosclerosis. Heart Fail Clin 2012; 8:575-87.

  20. Katsiki N, Papadopoulou SK, Fachantidou AI, Mikhailidis DP. Smoking and vascular risk: Are all forms of smoking harmful to all types of vascular disease? Public Health 2013; 127:435-41.

  21. Vazzana N, Santilli F, Sestili S, Cuccurullo C, Davi G. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr Med Chem 2011; 18:5267-80.

  22. Cronin O, Morris DR, Walker PJ, Golledge J. The association of obesity with cardiovascular events in patients with peripheral artery disease. Atherosclerosis 2013;228:316-23.

  23. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: Molecular mechanisms and clinical implications. J Cardiol 2012;59:235-42.

  24. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;132:612-28.

  25. Williams PT. Physical fitness and activity as separate heart disease risk factors: A meta-analysis. Med Sci Sports Exerc 2001;33:754-61.

  26. Gu HF, Tang CK, Yang YZ. Psychological stress, immune response, and atherosclerosis. Atherosclerosis 2012;223:69-77.

  27. McGill HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, Strong JP. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105:2712-8.

  28. Goodman DS, Hulley SB, Clark LT, Davis CE, Fuster V, La Rosa JC, et al; for the Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Archives of Internal Medicine 1988;148:36-69.

  29. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269: 3015-23.

  30. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

  31. Rudolf J, Lewandrowski KB. Cholesterol, lipoproteins, highsensitivity C-reactive Protein, and other risk factors for atherosclerosis. Clin Lab Med 2014;34:113-27.

  32. Seishima M. Treatment for dyslipidemia- A strategy for the prevention of atherosclerosis. Rinsho Byori 2013;61:334-41.

  33. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011;13:544-52.

  34. Breuer HW. Hypertriglyceridemia: A review of clinical relevance and treatment options: Focus on cerivastatin. Curr Med Res Opin 2001;17:60-73.

  35. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B-69B.

  36. Koba S. Statin therapy for atherogenic hypertriglyceridemia. Nihon Rinsho 2013;71:1655-60.

  37. Elshourbagy NA, Meyers HV, Abdel- Meguid SS. Cholesterol: The good, the bad, and the ugly- Therapeutic targets for the treatment of dyslipidemia. Med Princ Pract 2014;23:99-111.

  38. Feig JE, Hewing B, Smith JD, Hazen SL, Fisher EA. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res 2014;114:205-13.

  39. Ginter E, Simko V. New promising potential in fighting atherosclerosis: HDL and reverse cholesterol transport. Bratisl Lek Listy 2013;114:172-6.

  40. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am 2012;96:13-26.

  41. Ference BA, Mahajan N. The role of early LDL lowering to prevent the onset of atherosclerotic disease. Curr Atheroscler Rep 2013;15:312.

  42. Chan DC, Ng TW, Watts GF. Apolipoprotein A-II: Evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis. Ann Med 2012;44:313-24.

  43. Imes CC, Austin MA. Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics. Biol Res Nurs 2013;15: 292-308.

  44. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ 2013;22:399-411.

  45. Rosen BD, Litwin SE. The expanding role of computed tomography in the assessment of coronary artery disease and cardiac anatomy. Trends Cardiovasc Med 2011;21:193-9.

  46. Makowski MR, Henningsson M, Spuentrup E, Kim WY, Maintz D, Manning WJ, Botnar RM. Characterization of coronary atherosclerosis by magnetic resonance imaging. Circulation 2013;128:1244-55.

  47. Tobis JM, Nalcioglu O, Henry WL. Digital subtraction angiography. Chest Journal 1983; 84:68-75.

  48. Weinstein PR. Digital subtraction angiography. Clinical Neurosurgery 1982;31:90-106.

  49. Harrington DP, Boxt LM, Murray PD. Digital subtraction angiography: Overview of technical principles. Am J Roentgenol 1982;139:781-6.

  50. Neeley JP 3rd, Vannier MW, Gutiérrez FR, Spadaro JJ Jr. Digital subtraction angiography of the coronary arteries. Crit Rev Diagn Imaging 1985;25:23-60.

  51. Lu M, Wang J, Li CM, Chen W, Li HC, Zhang L. Evaluation of intracranial aneurysms using dual-source computed tomographic angiography and digital subtraction angiography. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2010; 32:615-8.

  52. Bharath RD, Vasudev MK, Jayakumar PN, Goel G, Kovoor JM, Ravishankar S, Thennarasu K. Comparative study evaluating the in vivo characteristics of ruptured and unruptured aneurysms using serial Digital Subtraction Angiography. Neuroradiol J 2009; 22:581-7.

  53. Allain CC, Poon LS, Chan CS, Richmond WFPC, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.

  54. Nagele U, Hagele EO, Sauer G, Wiedemann E, Lehmann P, Wahlefeld AW, Gruber W. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem 1984;22:165-74.

  55. Assmann G, Schriewer H, Schmitz G, Hägele EO. Quantification of highdensity- lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 1983;29; 2026-30.

  56. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.

  57. Coniglio RI. Determinación de apolipoproteína B por electroinmunodifusión en pacientes normo- e hiper-colesterolémicos. Acta Bioquím Clin Lat 1983;17:401-8.

  58. López J, Hilerita J, Díaz N. Estudio comparativo de los diferentes métodos inmunoquímicos para la cuantificación de apolipoproteínas B. Posibilidades de introducción en nuestro sistema de salud. Rev Cubana Med 1987;29:1060-8.

  59. Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem 1986;32:957-61.

  60. Santana Porbén S, Martínez Canalejo H. Manual de Procedimientos Bioestadísticos. Segunda Edición. EAE Editorial Académica Española. ISBN- 13: 9783659059629. ISBN-10: 3659059625. Madrid: 2012.

  61. Nicholls SJ, Andrews J, Puri R, Uno K, Kataoka Y. Imaging progression of coronary atherosclerosis. Circ J 2013; 77:3-10.

  62. Skrede S, Kvarstein B. Hyperlipidemia in peripheral atherosclerotic arterial disease. Acta Chir Scand 1975;141: 333-40.

  63. Trianti M, Xanthos T, Iacovidou N, Dagres N, Lekakis JP, Kyriakou F, Kremastinos DT. Relationship between individual cardiovascular risk factors and localization of coronary atherosclerotic lesions. Heart Lung 2011;40:201-7.

  64. Rössner S, Kjellin KG, Mettinger KL, Sidén A, Söderström CE. Dyslipoproteinemia in patients with ischemic cerebro-vascular disease: a study of stroke before the age of 55. Atherosclerosis 1978;30:199-209.

  65. Gobal FA, Mehta JL. Management of dyslipidemia in the elderly population Ther Adv Cardiovasc Dis 2010;4: 375-83.

  66. Walsh JM. Lipids in women: Screening and treatment. J Am Med Womens Assoc 2003; 58:240-7.

  67. Preobrazhenskiĭ DV, Sidorenko BA, Pataraia SA, Vyshinskaia ID, Borisenko OV. Hypercholesterolemia in men and women of various ages. Part I. Clinical and prognostic significance. Kardiologiia 2007;47:84-9.

  68. Crandall CJ, Barrett-Connor E. Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: A systematic review. Endocrinol Metab Clin North Am 2013; 42:227-53.

  69. Herrera Gómez V, Rodríguez Domínguez L, González O’Farrill S, La O Herrera I, Mas Gómez M, Valdés Almaral O, et al. La Gran Crisis Aterosclerótica en mujeres perimenopausicas de un área primaria de salud de La Habana. Frecuencia y factores de riesgo. RCAN Rev Cubana Aliment Nutr 2009;19:26-37.

  70. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A metaanalysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370(9602):1829-39.

  71. Fuchs FD, Fuchs SC, Moreira LB, Gus M. Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities. Vasc Health Risk Manag 2012;8:437-42.

  72. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon F, Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF. Lack of association between cholesterol and coronary heart disease mortality and morbidity and allcause mortality in persons older than 70 years. JAMA 1994;272:1335-40.

  73. Brescianini S, Maggi S, Farchi G, Mariotti S, Di Carlo A, Baldereschi M, Inzitari D, for the ILSA Group. Low total cholesterol and increased risk of dying: are low levels clinical warning signs in the elderly? Results from the Italian Longitudinal Study on Aging. J Am Geriatr Soc 2003;51:991-6.

  74. Ranieri R, Rozzini S, Franzoni P, Barbisoni M, Trabucchi P. Serum cholesterol levels as a measure of frailty in elderly patients. Exp Aging Res 1998; 24:169-79.

  75. Barreto Penie J, Santana Porbén S, Consuegra Silverio D. Intervalos de referencia locales para la excreción urinaria de creatinina en una población adulta. Nutrición Hospitalaria [España] 2003;18:65-75.

  76. Pakkal M, Raj V, McCann GP. Noninvasive imaging in coronary artery disease including anatomical and functional evaluation of ischaemia and viability assessment. Br J Radiol 2011; 84(Spec No 3):S280-95.

  77. Rosen BD, Litwin SE. The expanding role of computed tomography in the assessment of coronary artery disease and cardiac anatomy. Trends Cardiovasc Med 2011;21:193-9.

  78. Makowski MR, Botnar RM. MR imaging of the arterial vessel wall: Molecular imaging from bench to bedside. Radiology 2013;269:34-51.

  79. Makowski MR, Henningsson M, Spuentrup E, Kim WY, Maintz D, Manning WJ, Botnar RM. Characterization of coronary atherosclerosis by magnetic resonance imaging. Circulation 2013;128:1244-55.

  80. Kaneda H, Terashima M, Yamaguchi H. The role of intravascular ultrasound in the determination of progression and regression of coronary artery disease. Curr Atheroscler Rep 2012;14:175-85




2020     |     www.medigraphic.com